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circulation is found as a disulfi de — either 
as a mixed disulfi de with protein, or as a 
low molecular species (homocystine and 
homocysteine–cysteine mixed disulfi de). 
Th erefore, effi  cacious treatment of hyperho-
mocysteinemia must result in the lowering 
of all disulfi de forms of homocysteine. As 
Perna et al.4 and others have shown, this is 
usually not possible in patients with ESRD 
when current therapeutic approaches are 
used. Patients with ESRD have much higher 
levels of tHcy than patients with coronary 
artery disease. A concerted eff ort is needed 
to identify homocysteinylated proteins in 
the ESRD patient population. Alternatively, 
experiments should be designed to isolate 
and identify homocysteinylated proteins 
from in vivo rather than in vitro settings. 
Protein homocysteinylation, whether it be 
N-linked or S-linked, may be the underly-
ing mechanism in homocysteine causality.
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Adenosine and dialysis 
hypotension
CFM Franssen1
In this issue, Imai et al. report the results of a double-blind placebo-
controlled study on the effect of an adenosine A1 receptor antagonist, 
FK352, on the incidence of dialysis hypotension in hypotension-prone 
patients. This Commentary discusses the use of selective adenosine A1 
receptor antagonists for the prevention of dialysis hypotension from the 
perspective of the potential role of adenosine in its pathogenesis.
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Dialysis hypotension
Dialysis hypotension is one of the most 
frequent complications of hemodialysis 
and can lead to serious vascular events 
such as cerebral, cardiac, and mesenteric 
ischemia or infarction. Frequent dialysis 
hypotension contributes to overhydration 
because of an inability to reach dry weight 
and may lead to underdialysis because of 
interruptions or early termination of the 
dialysis session.
Th e cause of dialysis hypotension is mul-
tifactorial. Th e basic concept, however, is 
that frank hypotension occurs only when 
cardiovascular compen satory mecha-
nisms do not adequately compensate for 
the inevitable blood volume reduction that 
results from the imbalance between the 
ultrafi ltration rate and the plasma refi lling 
rate.1 Sudden hypotension can be triggered 
especially by activation of the sympatico-
inhibitory cardiopressor refl ex (Bezold-Jar-
isch refl ex) in the context of a critical blood 
volume decline, impaired cardio vascular 
compensatory mechanisms, and cardiac 
underfi lling.2 Structural cardiovascular 
changes such as left  ventricular hypertro-
phy and diastolic dysfunction also play an 
important role, as these conditions oppose 
ventricular fi lling and predispose to a fall in 
end-diastolic volume and stroke volume.
Standard measures to prevent or alle-
viate dialysis hypotension include care-
ful assessment of dry weight, limitation 
of fl uid and salt intake, reduction of the 
dialysate temperature, abstinence from 
food during hemodialysis, use of bicar-
bonate instead of acetate as buff er in the 
dialysate, avoidance of low-sodium and 
low-calcium dialysate, and adjustment of 
the dosage and/or time of administration 
of antihypertensive drugs. Notably, one 
of the most eff ective strategies to prevent 
dialysis hypotension is to increase the 
dialysis time and/or the dialysis frequency, 
for example by short daily hemodialysis 
or frequent nocturnal (home) hemodialy-
sis. Finally, several classes of drugs have 
been reported to decrease the incidence 
of dialysis hypotension: for instance, the 
selective α1 adrenergic agonist midodrine, 
the norepinephrine precursor l-threo-3,4-
dihydroxyphenylserine (L-DOPS), and 
the selective serotonin reuptake inhibi-
tor sertraline hydrochloride. Imai et al.3 
(this issue) now add a new class of drugs, 
the adenosine A1 receptor antagonists, to 
the therapeutic arsenal to combat dialysis 
hypotension. Drug treatment for dialysis 
hypotension, however, should be consid-
ered only when the measures listed above 
fail to prevent hypotension.
Adenosine
Adenosine is an endogenous purine nucle-
oside with vasodilating, cardio depressant, 
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and cardioprotective properties. Adeno-
sine is released by endothelial cells and 
vascular myocytes, particularly during 
ischemia. Adenosine triphosphate and 
adenosine are also released by sympa-
thetic fi bers and by poorly myelinated or 
nonmyelinated fi bers (discussed by Saad-
jian et al.4).
Th e eff ects of adenosine are mediated 
by specifi c cell-surface receptors.5 Adeno-
sine-induced artery relaxation is mediated 
by adenosine A2 receptors. Th e activation 
of A1 receptors mediates cardiac depres-
sion through negative chronotropic and 
inotropic eff ects and diminishes blood 
vessel tone via the prejunctional inhibi-
tion of neurotransmitter release on the 
perivascular sympathetic and capsaicin-
sensitive sensory aff erents.4 Importantly, 
stimulation of adenosine A1 receptors by 
adenosine triggers and mediates ischemic 
preconditioning of cardiac muscle, which 
delays ischemia-induced cell death and 
decreases infarct size.6
Adenosine has a very short half-time 
(seconds), because there is rapid scav-
enging by many types of cells, including 
erythrocytes, and because it is rapidly 
degraded. Rapid changes in plasma ade-
nosine concentrations are, therefore, dif-
fi cult to detect. Metabolites of adenosine 
such as inosine and hypoxanthine are 
more stable, and plasma levels are thought 
to refl ect adenosine release.
What is the evidence that adenosine 
plays a role in dialysis hypotension?
Patients on maintenance hemodialysis were 
found to have increased predialysis plasma 
levels of adenosine and inosine in compari-
son with healthy controls and patients on 
peritoneal dialysis.7 During hemodialysis, 
plasma levels of adenosine and inosine rose 
even further compared with predialysis 
levels.7 A previous study reported higher 
intradialytic plasma concentrations of ade-
nosine metabolites in patients who were 
dialyzed with an acetate-based dialysate 
in comparison with patients on a bicarbo-
nate-based dialysate.8 Th is fi nding can be 
explained by the conversion of acetate to 
lactate in the liver, a process that involves 
dephosphorylation of adenosine triphos-
phate to adenosine monophosphate, which 
is converted to adenosine in a concentra-
tion-dependent manner.
To date, there are two studies from one 
group that have addressed the relationship 
between dialysis hypotension and plasma 
levels of adenosine metabolites.9,10 Shin-
zato et al. showed that sudden, but not 
gradual, intradialytic hypotension was 
associated with increases in plasma levels 
of adenosine metabolites in comparison 
with predialysis and prehypotension lev-
els.9,10 In light of their fi ndings, Shinzato 
et al. postulated an interesting hypothesis 
on the pathogenic role of adenosine in 
dialysis hypotension (Figure 1). However, 
elevated levels of adenosine metabolites 
do not prove that adenosine plays a patho-
genic role, as adenosine release may have 
simply resulted from tissue ischemia that 
accompanied the sudden hypotension. 
Notably, in the fi rst study of Shinzato et 
al., the blood pressure nadir was much 
lower in patients with sudden hypotension 
than in those with gradual hypotension.9 
In their second study, blood pressure data 
were not reported.10 Until now, the rela-
tionship between sudden dialysis hypo-
tension and increased plasma levels of 
adenosine metabolites has not been con-
fi rmed by other groups.
Indirect evidence for a role of adeno-
sine was sought by adenosine receptor 
blockade by the nonselective (A1 and A2) 
adenosine receptor antagonist caff eine. 
In a placebo-controlled crossover study, 
caff eine was indeed found to prevent sud-
den, and not gradual, intradialytic hypo-
tension.10 However, caffeine has other 
cardiovascular eff ects besides adenosine 
receptor antagonism that may have led to 
its benefi cial eff ect.
The nucleoside transport inhibitor 
dipyridamole inhibits cellular uptake of 
adenosine and increases its half-time. If 
adenosine indeed plays an important role 
in the pathogenesis of dialysis hypoten-
sion, one would expect the use of dipyri-
damole to be associated with an increased 
incidence of dialysis hypotension. How-
ever, to my knowledge, no studies have 
linked chronic dipyridamole use to an 
increased incidence of dialysis hypoten-
sion. Th e lack of such reports, however, 
does not rule out such a relationship.
There are interesting similarities 
between sudden dialysis hypotension 
and disorders characterized by sudden 
hemodynamic instability due to auto-
nomic neuropathy, such as neurocardio-
genic syncope. Both are characterized by 
relative or absolute bradycardia, sudden 
hypotension, and arterial vasodilatation. 
A paradoxical withdrawal of central sym-
pathetic outfl ow is thought to play a role 
in these disorders. Exogenous adenosine 
or adenosine triphosphate is an effec-
tive agent for the provocation of neurally 
mediated syncope in susceptible patients.4 
Patients with unexplained syncope who 
had a positive tilt test were found to have 
elevated baseline adenosine plasma levels. 
Adenosine plasma levels rose signifi cantly 
during tilt testing-induced syncope in 
these patients.4
FK352 for the prevention of dialysis 
hypotension?
In the well-designed study of Imai et al., 
FK352 had a signifi cant but modest eff ect 
on the incidence of dialysis hypotension.3 
Overall, FK352 reduced the occurrence 
of intradialytic hypotension by 12.8% in 
comparison with that seen during the 
observation period. Th e incidence of dial-
ysis hypotension during the active treat-
ment period did not diff er signifi cantly 
Figure 1 | Hypothesis on the role of adenosine 
in dialysis hypotension. A decrease in 
circulating blood volume may lead to tissue 
ischemia, either as a result of vasoconstriction 
in certain vascular beds (for example, the 
splanchnic circulation) or as a result of 
hypovolemia-induced systemic arterial 
hypotension. The ischemia results in increased 
local adenosine release, which causes inhibition 
of norepinephrine release, vasodilation, and a 
decrease in heart rate and contractitily. These 
adenosine-mediated cardiovascular effects 
result in deepening hypotension.9,10
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between FK352 (56.1%) and placebo 
(62.5%). During the observation period, 
the incidence of dialysis hypotension was 
slightly higher in the FK352 (68.4%) than 
in the placebo group (54.2%). Imai et al. 
do not provide data on the cardiovascular 
comorbidity of the study group. Notably, 
patients randomized to FK352 were on 
dialysis signifi cantly longer than those 
randomized to placebo. Th erefore, it is 
possible that the FK352 group comprised 
more patients with serious cardiovascular 
comorbidity, contributing to the higher 
incidence of dialysis hypotension during 
the observation period.
Th e postdialysis weight was kept constant 
throughout the study. Weight is not the best 
marker of an adequate hydration status, 
as a change in lean body mass may occur 
unnoticed because of an opposite change 
in extracellular volume. However, unless 
FK352 infl uenced appetite, it is unlikely 
that a change in real dry weight infl uenced 
the results, because of the randomized and 
double-blind design of the study.
Imai et al.3 did not report plasma levels 
of adenosine (metabolites) to show that 
dialysis hypotension was indeed associated 
with increased adenosine release. Th ey did 
not perform detailed studies on the eff ects 
of FK352 with respect to the cardiovascu-
lar and autonomic nervous system.
Concluding remarks
Th e study of Imai et al.3 adds weight to the 
attractive hypothesis that adenosine plays 
a role in the pathogenesis of dialysis hypo-
tension. It is plausible that adenosine plays 
a role as a mediator in the deepening of 
hypotension. However, in my opinion, this 
concept is still not proven. Th e availabil-
ity of specifi c adenosine receptor antago-
nists, however, will undoubtedly facilitate 
future research to delineate the exact role 
of adenosine in dialysis hypotension. Such 
studies should preferably include detailed 
assessment of the eff ects of these drugs 
on vascular tone, heart function, and the 
autonomic nervous system.
At present, FK352 cannot be recom-
mended as a drug for prevention of 
dialysis hypotension. First, as Imai et al.3 
also point out, the optimal dose and time 
of administration must be determined. 
Next, efficacy should be confirmed in 
another clinical trial with hypotension-
prone dialysis patients. Finally, the safety 
of this class of drugs should be estab-
lished especially with regard to possi-
ble cardiovascular side eff ects. Special 
attention should be given to the possible 
occurrence of (silent) cardiac ischemia, 
as adenosine mediates thoracic chest 
pain in cardiac ischemia and adenosine 
A1 receptor antagonism may impair 
the occurrence of cardioprotective 
ischemic preconditioning.
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